Ethyl diazoacetate adds to 1,3-diarylpropenones in a regioselective fashion to give intermediate 4,5-dihydro-3H-pyrazole derivative; 1,3-hydride shift in the latter leads to formation of isomeric ethyl 4-aryl-5-aroyl-4,5-dihydro-1H-pyrazole-3-carboxylate and ethyl 4-aryl-3-aroyl-4,5-dihydro-1H-pyrazole-5-carboxylate at a ratio of 5:1. Thermolysis of these products is not stereospecific; as a result, three isomeric substituted ethyl cyclopropanecarboxylates and 2-pyranone derivative are formed.
The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (I)-(I), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
本发明具有一系列抑制肿瘤坏死因子α(TNF-α)诱导坏死的杂环衍生物。本发明的杂环化合物由式(I)-(VIII)和化合物(I)-(I)、(13)-(26)、(27)-(33)、(48)-(57)和(58)-(70)描述。这些坏死素能抑制 FADD 缺陷变体人 Jurkat T 细胞中 TNF-α 诱导的坏死。本发明还具有以坏死素为特征的药物组合物。本发明的化合物和组合物还可用于治疗坏死蛋白可能起重要作用的疾病。